Champions Oncology Reports $59.4M Revenue and Outlines Fiscal 2027 Plan
Champions Oncology (NASDAQ: CSBR) reported fiscal Q4 results for the year ending in June, with annual revenue reaching a record $59.4 million. The company also achieved positive adjusted EBITDA of $1.6 million and maintained this performance across all four quarters. CEO Robert Brainin highlighted these achievements as meeting commitments to financial discipline while outlining plans for fiscal 2027 that include full funding for its Corellia platform, a key focus area. The company's consistent positive adjusted EBITDA in each quarter marks an important milestone and reflects improved operational efficiency. The announcement of the fully funded Corellia initiative signals strategic investment into future growth opportunities within oncology research and development.
Tickers: $CSBR
Topics: EBITDA management_commentary revenue